Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience. (Q54459895)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23283649%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

title

Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23283649%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

metastatic breast cancer

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23283649%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Fabiola Paiar

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23283649%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Pierluigi Bonomo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23283649%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Daniela Greto

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23283649%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Isacco Desideri

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23283649%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Luis Sanchez

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23283649%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

4

Gabriele Simontacchi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23283649%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

12

Lorenzo Orzalesi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23283649%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

10

Jacopo Nori

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23283649%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

8

Vieri Scotti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23283649%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

Lorenzo Livi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23283649%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Fiammetta Meacci

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23283649%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Sara Cecchini

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23283649%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Gianpaolo Biti

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23283649%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

3 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23283649%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23283649%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23283649%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23283649%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

434

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23283649%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12032-012-0434-2

21 February 2020

exact match

0 references

cites work

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0434-2

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0434-2

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0434-2

Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0434-2

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0434-2

A systematic review of taxane-containing regimens for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0434-2

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0434-2

Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0434-2

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0434-2

Detecting an overall survival benefit that is derived from progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0434-2

Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0434-2

The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23283649

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Bevacizumab improves the delivery and efficacy of paclitaxel

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23283649

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The microtubule-affecting drug paclitaxel has antiangiogenic activity

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23283649

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12032-012-0434-2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23283649%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference